참고문헌
- Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013). Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol, 36, 331-7. https://doi.org/10.1097/COC.0b013e318246b50d
- Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. https://doi.org/10.1056/NEJMoa032709
- Argyriou AA, Bruna J, Marmiroli P, Cavaletti G(2012). Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol, 82, 51-77. https://doi.org/10.1016/j.critrevonc.2011.04.012
- Argyriou AA, Polychronopoulos P, Iconomou G, et al (2007). Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol, 46, 1131-7. https://doi.org/10.1080/02841860701355055
- Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP(2010). Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON, 15, 435-46.
- Azadeh S, Moghimi-Dehkordi B, Fatem SR, et al (2008). Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev, 9, 123-6.
- Baek KK, Lee J, Park SH, et al (2010). Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat, 42, 185-90. https://doi.org/10.4143/crt.2010.42.4.185
- Cassidy J, Clarke S, Diaz-Rubio E, et al (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cance, 105, 58-64. https://doi.org/10.1038/bjc.2011.201
- Cassidy J, Tabernero J, Twelves C, et al (2004). XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 22, 2084-91. https://doi.org/10.1200/JCO.2004.11.069
- Cersosimo RJ(2005). Oxaliplatin-associated neuropathy: a review. The Annals of Pharmacology, 39, 128-35. https://doi.org/10.1345/aph.1E319
- Chau I, Cunningham D(2006). Adjuvant therapy in colon cancer- -what, when and how? Ann Oncol, 17, 1347-59. https://doi.org/10.1093/annonc/mdl029
- de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938
- Gamelin L, Boisdron-Celle M, Delva R, et al (2004). Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res, 10, 4055-61. https://doi.org/10.1158/1078-0432.CCR-03-0666
- Gamelin E, Gamelin L, Bossi L, Quasthoff S(2002). Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol, 29, 21-33. https://doi.org/10.1053/sonc.2002.33529
- Kalofonos HP, Aravantinos G, Kosmidis P, et al (2005). Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol, 16, 869-77. https://doi.org/10.1093/annonc/mdi193
- Kono T, Satomi M, Asama T, et al (2010). Cetuximabinduced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol, 1, 97-101.
- Meyerhardt JA, Tepper JE, Niedzwiecki D, et al (2004). Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol, 22, 648-57. https://doi.org/10.1200/JCO.2004.07.121
- Park SB, Goldstein D, Lin CS, et al(2009). Acute abnormalities of sensory nerve function associated with oxaliplatininduced neurotoxicity. J Clin Oncol, 27, 1243-9. https://doi.org/10.1200/JCO.2008.19.3425
- Payandeh M, Sadeghi M, Sadeghi E, Gholami F (2015). Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prev, 3, 19-22.
- Rothenberg ML, Cox JV, Butts C, et al (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol, 19, 1720-6. https://doi.org/10.1093/annonc/mdn370
- Saif MW, Wilson RH, Harold N, et al (2001). Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs, 12, 525-31. https://doi.org/10.1097/00001813-200107000-00006
- Sittl R, Lampert A, Huth T, et al (2012). Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A, 109, 6704-9. https://doi.org/10.1073/pnas.1118058109
- Stone WL, Krishnan K, Campbell SE, et al (2004). Tocopherols and the treatment of colon cancer. Ann NY Acad Sci, 1031, 223-33. https://doi.org/10.1196/annals.1331.022
- Storey DJ, Sakala M, McLean CM, et al (2010). Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol, 21, 1657-61. https://doi.org/10.1093/annonc/mdp594
- Vincenzi B, Frezza AM, Schiavon G, et al (2013). Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer, 21, 1313-9. https://doi.org/10.1007/s00520-012-1667-5
피인용 문헌
- Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk vol.159, pp.2, 2016, https://doi.org/10.1007/s10549-016-3939-0
- Fit for Chemo: Nerves May Thank You vol.109, pp.2, 2017, https://doi.org/10.1093/jnci/djw208
- Chemotherapy-induced peripheral neuropathy: A current review vol.81, pp.6, 2017, https://doi.org/10.1002/ana.24951
- Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4869-5
- Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study pp.1880-4233, 2018, https://doi.org/10.1007/s12282-018-0919-8
- Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort vol.89, pp.6, 2018, https://doi.org/10.1136/jnnp-2017-317215